Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249257 · ClinicalTrials.gov registry record
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- 20
- Enrollment target
NCT05249257: Completed study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT05249257 is a clinical trial that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05249257 has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.
Primary Outcome
Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from "+3" (very much improved) to "-3" (very much worse) to determine the degree of improvement of the treated areas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2022-09-12 |
What the finished NCT05249257 record still lists
NCT05249257 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05249257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05249257 about?
NCT05249257 is a clinical study titled "Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity". All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.
What is the current status of trial NCT05249257?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2022-01-25. Estimated completion is 2022-09-12.
Who is sponsoring clinical trial NCT05249257?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI